United States

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, currently in Phase II clinical trial for COVID-19 treatment. The company also develops other antiviral drugs for dengue, HCV, and other RNA viral infections. Atea has a license agreement with Merck & Co for the development and commercialization of ruzasvir for HCV treatment. The company was founded in 2012 and is based in Boston, Massachusetts.

Google

Ürün Müdürü

Veri Bilimci

Atea Pharmaceuticals

Atea Pharmaceuticals Açık Pozisyonlar

Kariyerinizi bir üst seviyeye çıkarmaya hazır mısınız? Atea Pharmaceuticals'deki bu açık pozisyonlara göz atın.